J&J, Bayer fail to win U.S. OK for expanded Xarelto use
If approved for acute coronary syndrome, Xarelto would compete with Effient from Indianapolis-based Eli Lilly and Co and Brilinta from London-based AstraZeneca Plc.
If approved for acute coronary syndrome, Xarelto would compete with Effient from Indianapolis-based Eli Lilly and Co and Brilinta from London-based AstraZeneca Plc.
The city of Indianapolis granted preliminary approval for an eight-year tax abatement to Arcamed Inc., which plans to purchase $1.4 million in equipment to design and manufacture titanium and case-tray systems for surgical instruments.
The local pharmaceutical giant plans to complete the program started in 2000 by repurchasing $420 million in shares by the end of the year. And on Tuesday, it declared a regular dividend of 49 cents.
The U.S. Supreme Court did not hand down a ruling in the health care reform case Monday morning. The nine justices meet again Thursday, but most observers expect the decision to come June 25 or June 28.
The skies got a little brighter for the orthopedic industry on Friday after Warsaw-based Biomet Inc. reported strong quarterly sales growth of 3.4 percent. That news sparked a small surge in the stock prices of two other Warsaw-based orthopedics companies.
Indianapolis-based WellPoint Inc. said it is lowering its profit forecast for the year by 3 percent after reaching a $90 million settlement in a class-action lawsuit.
The federal lawsuit was set to go to trial June 18 in Indianapolis. The claims arise from Anthem’s 2001 conversion from a mutual company, owned by its insured policyholders, to a public company.
Sam Odle, one of Indianapolis’ most prominent black business leaders, will be replaced on an interim basis by Jim Terwilliger while the hospital system conducts a national search for his successor.
Fishers-based Cancer-Free Lungs decided last year it was ready to shut down.
The Indian-born doctor is seeking past and future pay, in addition to other damages, for enduring what she considers harassment and discrimination while a resident at the Indianapolis hospital.
Eli Lilly and Co. has invested $20 million in Chinese pharmaceutical company Novast Labs in an effort to build up a portfolio of branded generic medicines in the fast-growing Asian market.
Some of the nation's biggest health insurers will keep some popular parts of President Barack Obama's health care overhaul even if the law fails to survive U.S. Supreme Court scrutiny later this month. Indianapolis-based WellPoint will wait for the court ruling.
Eli Lilly and Co. announced positive results for an experiemental insulin at the annual American Diabetes Association conference in Philadelphia, but was still upstaged by Denmark-based Novo Nordisk A/S.
Even though employers expect the U.S. Supreme Court to strike down at least some of the 2010 health reform law later this month, few are actually doing any contingency planning.
Republicans in the U.S. House joined with 37 Democrats to pass a bill repealing a medical-device tax, chipping away at the 2010 health-care law in a victory for companies including Indiana-based Zimmer Holdings Inc. and Boston Scientific Corp.
The Warsaw area is well-known as the home of gigantic orthopedic implant companies and their suppliers. But now a handful of startups have been able to raise nearly $25 million in equity investments despite the recession—putting a bit more fuel into a fairly stagnant entrepreneurial sector.
Health-care benefits would be offered to the domestic partners of Indianapolis city workers under a proposal introduced Monday night to the City-County Council.
The future of health insurance is lower profit margins and greater consumer control. WellPoint Inc. just bet $900 million on it.
It took the identification of 19 different genes for researchers at the Indiana University School of Medicine to develop a test for a rare form of cancer. But their gene-hunting has paid off, as a Texas-based company announced Monday the test is available for doctors to use.
WellPoint Inc. plans to buy lens retailer 1-800-Contacts Inc. in a deal worth an estimated $900 million, giving the insurer its first direct-to-consumer business outside selling individual health coverage.